Sight Sciences to Participate in the Upcoming Citi Virtual Healthcare Conference
Sight Sciences (Nasdaq: SGHT), an innovative eyecare technology company, announced its participation in the Citi Virtual Healthcare Conference scheduled for February 23, 2022, at 8:45 am PT. The management will engage in a fireside chat, accessible via a live and archived webcast on the company’s Investors section of its website. Sight Sciences focuses on transforming care standards through minimally invasive technologies, including the OMNI Surgical System for glaucoma and the TearCare System for dry eye treatment.
- None.
- None.
MENLO PARK, Calif., Feb. 21, 2022 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform standards of care and improve patients’ lives, today announced plans to participate in the upcoming Citi Virtual Healthcare Conference.
Sight Sciences’ management is scheduled to participate in a fireside chat February 23, 2022, at 8:45am PT. Interested parties may access a live and archived webcast of the fireside chat on the “Investors” section of the company’s website at: https://investors.sightsciences.com/.
About Sight Sciences
Sight Sciences is an eyecare technology company focused on developing and commercializing innovative solutions intended to transform standards of care and improve patients’ lives. Using minimally invasive or non-invasive approaches to target the underlying causes of the world’s most prevalent eye diseases, Sight Sciences seeks to create more effective treatment paradigms that enhance patient care and supplant conventional outdated approaches. The Company’s OMNI® Surgical System is a minimally invasive glaucoma surgery (MIGS) device indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma (POAG), the world’s leading cause of irreversible blindness. The Company’s TearCare® System is commercially available today as a wearable, office-based thermal eyelid technology that enables the controlled application of localized heat to the eyelids. The Company has a 510(k) pending for the clearance of the TearCare System for an expanded indication for the application of localized heat therapy in adult patients with evaporative dry eye disease due to meibomian gland dysfunction (MGD). For more information, visit www.sightsciences.com.
OMNI® and TearCare® are registered trademarks of Sight Sciences.
© 2022 Sight Sciences. All rights reserved.
Media contact:
Shay Smith
Health+Commerce
707.971.9779
shay@healthandcommerce.com
Investor contact:
Philip Taylor
Gilmartin Group
415.937.5406
Investor.Relations@Sightsciences.com
FAQ
When is Sight Sciences participating in the Citi Virtual Healthcare Conference?
How can I access the Sight Sciences fireside chat?
What is the focus of Sight Sciences' technologies?
What are the products highlighted by Sight Sciences?
What is the ticker symbol for Sight Sciences?
